bluuebunny/crossref_metadata_2025_split huggingface dataset:
P01-17 - Hypertension in Comorbidity with Depression
Authors: Burgic-Radmanovic M. , Trkulja D. , Banjac V. , Burgic S. , Dragojevic S. , Nikolic A. 
Published: June 2010

IntroductionNumerous researches show significant presence of cardiovascular disorders, especially hypertension in depressed patients that show up several years after first depressive episode.Mortality caused by cardiovascular disorders in depressed patients is 50% higher than in general population. Comorbid depression and cardiovascular disorders is making worse health condition, increasing suffering, making hard treatment, and outcome is not good.ObjectiveThe goal is to confirm presence of hypertension in depressed patients as the most common comorbid cardiovascular diseases.MethodA retrospective study has been conducted using data from medical history of 274 depressed patients hospitalized and treated at the Psychiatric Clinic, Clinical Center Banjaluka. These parameters were assessed: sex, age, number of hospitalizations, marital and employer status, comorbid disease, BMI, presence of hypertension, lipid status and glicemia's level. Data were presented using tables and graphs.ResultsResults obtained in our study were:Hypertension in comorbidity with depression was found in 106 patients (38,5%), 75 of them were males and 31 of them were females. The majority were at age 40-60 years. Obesity was found in 21% of them. High lipid's level was found in 20% of them. 11% of patients had high level of glicemia. More than half of the patients had lower socio-economic status.ConclusionDepression is often accompanied by cardiovascular disorders. It is very important to recognize this comorbidity in order to treat it successfully and to make better treatment's outcome.
P01-18 - Combined Antidepressant and Quetiapine Therapy in Bipolar I Mixed
Authors: Callista G. , Daneluzzo E. 
Published: June 2010

IntroductionMixed state, since Kraepelin's pioneering contribution, refers to an affective condition in which various admixtures of depressive and manic symptoms occur simultaneously.ObjectiveTo evaluate the efficacy and safety of quetiapine plus ADs, both SSRIs and SNRIs in the treatment of acute mixed episodes of Bipolar I Disorder patients.MethodWe pooled data from two ours independent studies for a total of 44 inpatients, 21 male and 23 female, diagnosed with type I mixed Bipolar Disorder (DSM-IV-TR). After receiving open-label quetiapine for 2 weeks, patients were subsequently randomised to receive either treatment with quetiapine + ADs or quetiapine alone for 18 weeks. Pooling the data, 22 received quetiapine alone (10 XRquetiapine) and the other were treated with an association of quetiapine plus an antidepressant. We evaluated these patients every week during the first month and every two weeks after that, using YMRS, HAMD-21.ResultsThe efficacy over depressive symptoms was similar in both groups. Compared with the baseline YMRS, at week 6 the percentage of improved YMRS responder was better in the group receiving quetiapine plus antidepressants than quetiapine alone. Three YMRS item scores improved significantly at week 6 in the group quetiapine plus AD(irritability, disruptive-aggressive behaviour and insomnia).ConclusionWe suggest that adding an AD in order to treat every main features of mixed episode further improved the outcome, probably due to a specific action on a particular subtype of mixed state. In particular, the dysphoric subtype along with irritability and insomnia manic factors, seem to be better responsive to AD supplementation.
P01-25 - ‘Non-compliance and Dysthimia, in Long-term Diabetics and Diabetic Limb Losses’- have we got a Role Here?
Authors: de los Santos R. , Ashrafi M. , Lamont P. , Pawape G. 
Published: June 2010

ObjectivesChronic diabetics at some point gives up their vigilance in the sugar control. Many of them end up with intractable diabetic feet with limb losses incurring health budget, enormous morbidity and mortality.Methods300 patients who presented with diabetic feet been interviewed and noticed that ‘few weeks or months prior to their start of symptoms a major change in the treatment mechanism happens which lead to catastrophic complications of Diabetes’. They do not qualify according to DSM IV classification to be called MDE. But can be called Dysthymia. Surgical, Medical, Vascular and Psychiatric units in an Australian Hospital have been involved in these interviews (a simple questionnaire). Personal audit in two countries (Fiji Islands & Bangladesh) where Diabetes is pretty alarming in number have been included in the data.ResultsDiabetic patients over time develop Dysthymia when they feel hopeless about control of their illness. Often they are overwhelmed by thoughts of long-term complications like retinopathy, neuropathy that they give up hope that they could combat its complications. Diabetic educators should be involved during their early stage of their illness before complications set in and should be trained to pick up dysthymic signs and symptoms for prompt referral for early psychological and psychiatric intervention.Conclusions:•Diabetic feet are preventable.•Early psychiatric assessment is helpful.•Preventive steps are cost effective.•Should Psychiatry Department have a role in the multidisciplinary management team of Diabetes?
P01-28 - Behavioural Addictions in Bipolar Disorder Patients: Role of Impulsivity and Personality Dimensions
Authors: Di Nicola M. , Tedeschi D. , Mazza M. , Martinotti G. , Harnic D. , Catalano V. , Bruschi A. , Pozzi G. , Bria P. , Janiri L. 
Published: June 2010

ObjectivesBehavioural addictions (BAs) can be understood as disorders characterized by repetitive occurrence of impulsive and uncontrolled behaviours. Very few studies have investigated their association with mood disorders. The present study was undertaken to determine the prevalence of the main behavioural addictions in a sample of bipolar outpatients in euthymic phase or stabilised by medications and to investigate the role of impulsivity and temperamental and character dimensions.MethodsOne-hundred-fifty-eight Bipolar Disorder (BD) (DSM-IV) outpatients were assessed with tests designed to screen the main behavioural addictions: pathological gambling (SOGS), compulsive shopping (CBS), sexual (SAST), internet (IAD), work (WART) and physical exercise (EAI) addictions. TCI-R and BIS-11 were administered to investigate impulsivity and personality dimensions mainly associated with BAs. The clinical sample has been compared with 200 matched healthy control subjects.ResultsIn bipolar patients, 33% presented at least one BA respect to the 13% of controls. Significantly higher scores at the scales for pathological gambling (p< .001), compulsive buying (p< .05), sexual (p< .001) and work addictions (p< .05) have been found. Self-Directness (p=.007) and Cooperativeness (p=.014) scores were significantly lower while impulsivity level was significantly higher (p=.007) in bipolar patients with BA than those without BA.ConclusionsTo our knowledge, this is the first study investigating the prevalence of behavioural addictions in BD showing a significant association of these disorders. BAs are more frequent in bipolar patients than in healthy controls and are related to higher impulsivity levels and character immaturity.
P01-31 - Use of Aripiprazole and Paroxetine in the Treatment of Patient with Bipolar Depression (Bipolar Disorder II, BDII) Case Report
Authors: Elezi F. , Tomori S. , Sotiri E. 
Published: June 2010

BackgroundTreatment of BDII may place the physician in difficulty because of the treatment resistence.Methods2 male patients 48 and 52 years old diagnosed with BDII (according to DSM IV) lastest episode, major depressive episode, with a poor or partial response to long-term treatment with antidepressant, mood stabilizer and sometimes antipsychotic drugs during the presence of psychotic symptoms.During last year their treatment was: Paroxetine 40mg/ 2x day and Lamotrigine 150mg/day. Because of the lack of response the treatment was changed as follows:Remove of lamotrigine; decrease of paroxetine to 20 mg; adding Aripiprazole 15 mg.BPRS, HAMD and CGI-severity were used to evaluate their symptoms and gravity.ResultsAfter 2 weeks of treatment significant improvement was noticed. This includes depressive and psychotic symptoms, sleep, anxiety and cognitive symptoms. Increase of professional performance.After using this combination, they started psychosocial rehabilitation program. Since September 2007 their situation is stabile and there have not been noticed recurrences.ConclusionsFavorable clinical results were noticed to both patients, with no noticeable adverse side effects. Aripiprazole combined with Paroxetine has improved depressive and psychotic symptoms of these patients with bipolar depression.Our findings suggest that Aripiprazole - Paroxetine is a safe and tolerable combination; however, control trials are needed to validate our findings.
P01-36 - Depression and Psychosomatic Diseases
Authors: Gabos Grecu M. , Gabos Grecu I. , Moica T. , Vesa A. , Gabos Grecu C. 
Published: June 2010

The aim of our retrospective study was to evaluate patients with depressive mood disorder, hospitalized in First Psychiatry Clinic of Tirgu Mures, Romania, between 01.01.2008 - 31.12.2008. We tried to demonstrate the link between depressive mood disorders and certain psychosomatic diseases associated, such as hypertension, coronary artery disease, hypothyroidism, gastrointestinal disorders, diabetes and duodenal ulcer.Methods517 patients with a diagnosis of major depressive disorder were evaluated in the period January to December 2008 in First Psychiatry Clinic of Tirgu Mures. The data obtained were entered into computer, processed and were compared statistically with data from literature.Results380 of the 517 patients suffer from one or more psychosomatic diseases. The majority patients with depressive mood disorders and psychosomatic illness associated were between 50 and 59 years old. The incidence of these diseases is more common in female sex. 75% of all patients hospitalized for these diseases are women. The most common disease associated with depression was hypertension. It is followed by coronary artery disease, gastrointestinal disorders, hypothyroidism, type 2 diabetes mellitus and duodenal ulcer. The most common gastrointestinal disorders were chronic gastrointestinal, chronic recto colitis and gastro duodenal ulcer.ConclusionsDepression is one of the most common disease for which patients are presented in specialty medical practices and psychiatric hospitals. Frequently, the psychiatric disorder is associated with some psychosomatic diseases that can decrease compliance of these patients and worsen long-term prognosis of the psychiatric disease.
P01-40 - Differential Association of Aggressive Traits with the 5-HTTLPR s Allele in Depressed and Healthy Women
Authors: Gonda X. , Fountoulakis K.N. , Lazary J. , Sasvari-Szekely M. , Veres-Szekely A. , Bagdy G. , Faludi G. , Rihmer Z. 
Published: June 2010

ObjectiveSuicide is a multicausal phenomenon posing a great challenge to medicine and society, yet we still have limited knowledge concerning underlying biochemical, neuroanatomical and genetic factors. Research increasingly points to a role of the serotonergic system, both on the level of suicidal behavior, and such behavioural traits which may serve as important intermedier endophenotypes in suicide research. Although results are conflicting, several studies described an association between the 5-HTTLPR polymorphism and suicide, as well as this polymorphism and certain aggressive traits. Impulsive aggression is also thought to play a major contributory role in suicide. The aim of our research was to investigate the association between the 5-HTTLPR and aggressive traits in depressive patients carrying a higher risk for suicide and healthy controls.Methods137 major depressive and 164 healthy controls women were recruited. Participants completed the Buss-Durkee Hostility Inventory and were genotyped for 5-HTTLPR. Association of aggressive traits and indeces with 5-HTTLPR genotype in the two groups were analysed using ANCOVA.ResultsDiagnosis and 5-HTTLPR genotype showed a significant association with aggressive traits. The pattern of association was different in the depressed and control groups. The strongest interaction effect between genotype and diagnosis was observable in case of Resentment.ConclusionWe found a significant association between 5-HTTLPR and several aggressive traits. In case of depressive patients the association was more marked. In depressed women the 5-HTTLPR shows a stronger association with aggressive traits related to aggression turned inward, which may play a role in the background of suicide.
P01-45 - Comorbidity Between Bipolar Disorders and Personality Disorders: an Observational Study
Authors: Harnic D. , Catalano V. , Mazza M. , di Nicola M. , Bruschi A. , Carnevale E. , di Felice C. , Cardella A. , Marano G. , Janiri L. , Bia P. 
Published: June 2010

ObjectivesThe aim of the present study was to thoroughly investigate the existing comorbidity between Axis II and Bipolar Disorder (BD) pointing out as well the meaningful existing comorbidity between Personality Disorders and Cyclothymia.Materials and methodsA study group composed of 70 patients affected by Bipolar Disorder (Type I, Type II, and Cyclothymia) was enrolled at the Bipolar Disorders Unit of the Catholic University of the Sacred Heart of Rome. Axis I diagnosis was made by SCID-I; Axis II diagnosis was made by SCID-II.ResultsIn a sample of 70 patients in euthymic phase, 39 patients (55.7%) showed comorbidity with Axis II Disorders. Clusters were represented as follows: 2 patients (5.1%) fell within cluster A; 24 patients (61.5%) within cluster B; 9 patients (23%) within cluster C; and 4 patients (10.4%) turned out to be affected by NAS Personality Disorders. On the whole 39 patients - 24 patients (61.5%) affected by BD I, 6 patients (15.3%) affected by BD II, and 9 patients (23.0%) affected by Cyclothymia were found to have comorbidity with Axis II Disorders. Besides, in our sample there was a significant comorbidity between Cyclothymia and Personality Disorders.DiscussionMore than half of patients (55.7%) showed comorbidity with Axis II Disorders. Moreover most of patients turned out to be affected by Personality Disorders falling within cluster B while 23% of Cyclothymic patients were found to have comorbidity with Axis II Disorders.
P01-61 - Impaired Decision-making in the 3 Phases of Bipolar Disorder : a Trait-related Deficit
Authors: Adida M. , Jollant F. , Clark L. , Mazzola-Pomietto P. , Kaladjian A. , Jeanningros R. , Goodwin G. , Azorin J.-M. , Courtet P. 
Published: June 2010

IntroductionBipolar disorder (BD) is associated with impaired psychosocial behaviours. Little is known about deficits in neurocognitive functions like decision-making possibly related both to these behaviours and to the nature of the disorder.ObjectivesTo determine whether decision-making impairments exist in manic (M), depressed (D) and euthymic (E) bipolar patients (BP) and to determine whether illness and course-of-illness characteristics can predict participants’ performanceMethodsA power analysis was conducted. A total of 315 subjects, including 45 M and 32 D inpatients and 90 E outpatients with BD I, medicated, and 150 Healthy Controls (HC), age, IQ and gender-matched, were included. Decision-making ability and sensitivity to punishment frequency were assessed with the Iowa Gambling Task (IGT).ResultsOn the IGT, MBP (p< 0.001), DBP (p< 0.01) and EBP (p< 0.05) selected significantly more cards from the risky decks than HC with no significant differences between BP groups. Unlike HC, MBP (p< 0.001), DBP (p< 0.05) and EBP (p< 0.05) showed little capacity to learn from incurred losses with no significant differences between BP groups, but, like HC, BP preferred decks that yielded infrequent penalties over those decks that yielded frequent penalties. In a multivariate analysis, decision-making impairment in the BP was significantly (p=0.001) predicted by low level of education, high total number of admissions and family history of BD.ConclusionsBP clearly show defects in decision-making predicted by course-of-illness illness characteristics. Impaired decision-making might be a trait-related neurocognitive deficit in BD and partly explain impaired psychosocial behaviours of BP.
P01-63 - An Audit to Compare Discharge Rates between Antidepressant Monotherapies Prescribed for Either Unipolar Depression or for other Indications
Authors: Agius M. , Gardner J. , Katie L. , Zaman R. 
Published: June 2010

BackgroundThere are differences in efficacy of commonly prescribed anti-depressants. Escitalopram, sertraline, venlafaxine and mirtazapine (‘the four’) were the most effective.ObjectivesTo compare the efficacy of ‘the four’ with other anti-depressant monotherapies prescribed either for the treatment of unipolar depression or other indications, using discharge rates as the outcome measure.MethodWe studied all patients on an antidepressant monotherapy in Bedford hospital (206 in total). We examined the clinical notes for each patient prescribed antidepressants to assess whether they were discharged from the out-patient clinic. Hence we calculated rates of discharge for ‘the four’ and other antidepressant monotherapies for patients with unipolar depression or another psychiatric condition.ResultsFor patients with unipolar depression, discharge rates were higher for ‘The four’. For patients with other indications, discharge rates were higher for other antidepressant monotherapies. A greater percentage of patients with unipolar depression were discharged from clinic compared with people treated for other indicationsDiscussionThis suggests that indication for which the antidepressant monotherapy is prescribed will affect the efficacy of treatment, as measured by discharge rates. The fact that a greater percentage of patients with unipolar depression were discharged from clinic compared with people treated for other indications may suggest that people with ‘treatment resistant depression’ may really have another disorder, for example borderline personality disorder, bipolar disorder or PTSD.ConclusionThis audit suggests that ‘the four’ are more effective for the treatment of unipolar depression compared with other indications, using discharge rates as the outcome measure.
P01-65 - A Comparison of Outcomes of Patients with Depression, Recurrent Depression, and Depression and Anxiety in a CMHT
Authors: Butler S. , Agius M. , Zaman R. 
Published: June 2010

BackgroundDepression treatment outcomes within British Community Mental Health Teams have not been adequately described.Aims/ObjectivesTo describe factors which influence outcome of depression within Bedford East CMHT.MethodsPatients with Depression F32, Recurrent Depression F33, and Depression and Anxiety F42.1 were identified from a database. Factors affecting outcomes, including Suicidal ideation, Alcohol problems, Drug problems, and use of Augmentation therapy, were identified. Outcome as measured by patient discharge was compared in the three groups.ResultsThe percentage of each group discharged was 12.24 for F32, 30.53 for F33, and 29.17 for F42.1.For F32 patients, the percentage of patients with suicidal ideation was 55.10, with alcohol problems was 32.65, with illicit drug problems was 14.28, while the percentage of patients on augmentation strategies was 38.77.For F33 patients, the percentage of patients with suicidal ideation was 27.37, with alcohol problems was 9.47, with illicit drug problems was 1.05, while the percentage of patients on augmentation strategies was 27.37.For F42.1 patients, the percentage of patients with suicidal ideation was 25, with alcohol problems was 8.33, with illicit drug problems was 8.33, while the percentage of patients on augmentation strategies was 54.17.Comment:Fewer discharges occurred from the F32 group, mirroring increased suicidality and drug and alcohol use in this group. There is no significant difference in the number of patients using augmentation strategies between the F32 and F33 groups. It does not appear that augmentation strategies for treating depression are having a clear influence on outcomes.
P01-67 - 5HT1A Agonist Activity and the Antidepressant Efficacy of Lu AA21004
Authors: Mayze T. 
Published: June 2010

ObjectivesTo discuss a case study that suggests advantages for the combination of 5HT transporter inhibition plus 5HT1A receptor agonism over transporter inhibition alone.MethodsNaturalistic clinical case study.ResultsThe patient had a documented 10 year history of poor response to SSRI's including s-citalopram. There was no suggestion of placebo response in the past. He responded well to Lu AA21004 and sustained this remission over a period of 9 months. He relapsed after Lu AA21004 was ceased. He recovered and again achieved a sustained remission after being prescribed a combination of s-citalopram plus pindolol.ConclusionsThe addition of pindolol (a 5HT1A receptor partial agonist) to s-citalopram adds 5HT1A receptor agonism to the 5HT transporter inhibition of s-citalopram. This is a similar profile to Lu AA21004. It is noted that Lu AA21004 also has 5HT3 receptor antagonism which is postulated to impact more on side effect profile than antidepressant efficacy. The current case strongly suggests that (in some instances at least) the addition of 5HT1A agonism to 5HT transporter inhibition might convert non-responders to responders and thus offer clinical advantage over transporter inhibition alone.
P01-79 - Pet-measured Occupancy of the D2 Receptor: a Comparison of Quetiapine Fumarate Immediate-and Extended-release Formulations in Healthy Subjects
Authors: Nyberg S. 
Published: June 2010

ObjectivesDeveloped as an antipsychotic, quetiapine displays moderate, transient occupancy of dopamine D2 receptors. Characterization of norquetiapine indicates this major human metabolite potently inhibits the norepinephrine transporter and binds to D2 receptors with affinity similar to quetiapine. Clinical pharmacology studies indicate pharmacodynamic differences between the immediate-release (IR) and the recently developed extended-release (XR) quetiapine formulation. The objectives of this study were to further investigate the pharmacokinetics of these formulations, and to relate D2-receptor occupancy to quetiapine and norquetiapine exposures.MethodsEleven healthy male volunteers, aged 20-45 years, underwent PET using the radioligand [11C]raclopride. After baseline measurements, quetiapine XR was administered once-daily for 8 days, with titration to 300 mg on Days 5-8. Quetiapine IR was administered at 300 mg daily on Days 9-12. PET measurements were repeated after the last doses of XR and IR at predicted times of Cmax. D2-receptor occupancy was calculated using a reference tissue model. Concomitant pharmacokinetic measurements were performed.ResultsFor quetiapine XR, mean D2-receptor occupancy at Cmax was 32% (SD ±11%; n=11). For quetiapine IR, mean D2-receptor occupancy at Cmax was 47% (SD ±9%; n=10). Quetiapine XR produced lower peak D2 occupancy than quetiapine IR in all subjects.ConclusionsPharmacokinetic differences between quetiapine XR and IR formulations translate to different profiles of brain receptor occupancy. Quetiapine XR was associated with lower peak D2-receptor occupancy than quetiapine IR at corresponding doses. This observation may provide important mechanistic underpinnings for emerging clinical data comparing the 2 quetiapine formulations.Supported by funding from AstraZeneca Pharmaceuticals LP.